Incident Report
Subform I: General Information
1. Report Type.
New incident report
Incident Report Number: 2023-3075
2. Registrant Information.
Registrant Reference Number: FMC-57307
Registrant Name (Full Legal Name no abbreviations): FMC of Canada Limited
Address: 6755 Mississauga Road, Suite 204
City: Mississauga
Prov / State: Ontario
Country: Canada
Postal Code: L5N7Y2
3. Select the appropriate subform(s) for the incident.
Scientific Study
4. Date registrant was first informed of the incident.
5. Location of incident.
6. Date incident was first observed.
Product Description
7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.
Active(s)
PMRA Registration No.
PMRA Submission No.
EPA Registration No.
Product Name: CHLORANTRANILIPROLE / CLOTHIANIDIN (X4G34)
- Active Ingredient(s)
- CHLORANTRANILIPROLE
- CLOTHIANIDIN
7. b) Type of formulation.
Application Information
8. Product was applied?
Unknown
9. Application Rate.
10. Site pesticide was applied to (select all that apply).
11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).
To be determined by Registrant
12. In your opinion, was the product used according to the label instructions?
Unknown
Subform VII: Scientific Study
1. Study Reference
Title Chlorantraniliprole/Clothianidin (X4G34) 500 G/L SC: (3:5): Avian Acute Oral Toxicity Study in Japanese Quails
Date 27-JAN-23
2. a) Is an extension needed to translate the document?
No
3. Type of incident identified in the study
Increased health or environmental risk
4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)
FMC recently sponsored an avian acute oral toxicity study on Japanese Quail with a blended product containing chlorantraniliprole (CAS No. 500008-45-7), and clothianidin (CAS No.: 210880-92-5). This blended product is not intended for U.S. registration. The toxicity endpoints reported arelower (more toxic) in the blended product than have been previously reported for chlorantraniliprole alone.
5. a) Was the study discontinued before completion?
No
5. b) Provide the reason for discontinuation
6. If the study is ongoing, what is the expected completion date?
For Registrant use only
7. Provide supplemental information here